↓ Skip to main content

Dove Medical Press

Article Metrics

Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal

Overview of attention for article published in Therapeutics and Clinical Risk Management, July 2011
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#28 of 1,060)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
1 news outlet
twitter
22 tweeters
patent
1 patent

Citations

dimensions_citation
38 Dimensions

Readers on

mendeley
29 Mendeley
Title
Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal
Published in
Therapeutics and Clinical Risk Management, July 2011
DOI 10.2147/tcrm.s23036
Pubmed ID
Authors

Nava Zisapel, Lemoine, Doron Garfinkel, Moshe Laudon, Nir

Abstract

Prolonged-release melatonin (PRM) 2 mg is indicated for insomnia in patients aged 55 years and older. A recent double-blind placebo-controlled study demonstrated 6-month efficacy and safety of PRM in insomnia patients aged 18-80 and lack of withdrawal and rebound symptoms upon discontinuation.

Twitter Demographics

The data shown below were collected from the profiles of 22 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 3%
Unknown 28 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 17%
Student > Master 4 14%
Other 3 10%
Professor > Associate Professor 3 10%
Student > Bachelor 2 7%
Other 6 21%
Unknown 6 21%
Readers by discipline Count As %
Medicine and Dentistry 11 38%
Agricultural and Biological Sciences 3 10%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Nursing and Health Professions 1 3%
Social Sciences 1 3%
Other 2 7%
Unknown 9 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 May 2020.
All research outputs
#814,409
of 15,860,480 outputs
Outputs from Therapeutics and Clinical Risk Management
#28
of 1,060 outputs
Outputs of similar age
#5,698
of 128,760 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#1
of 12 outputs
Altmetric has tracked 15,860,480 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,060 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 128,760 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.